Serum Concentrations of Vascular Endothelial Growth Factor in Infants Treated With Ranibizumab for Retinopathy of Prematurity
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 17
- 试验地点
- 1
- 主要终点
- The effect of intravitreal ranibizumab on serum VEGF level
研究概览
简要总结
To determine the serum concentrations of ranibizumab and vascular endothelial growth factor (VEGF) in infants with retinopathy of prematurity (ROP) who received intravitreal ranibizumab
详细描述
Infants with ROP are studied. They received 0.25 mg or 0.5 mg of intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases) with vascularly active ROP. Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab. The serum concentrations of ranibizumab and VEGF are measured by enzyme-linked immunosorbent assay, and the changes of the serum VEGF levels are determined.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 4 Weeks 至 3 Months（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Infants with vascularly active ROP
- •intravitreal ranibizumab
排除标准
- •already accepted laser therapy
研究组 & 干预措施
serum VEGF level
Serum samples are collected 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
干预措施: intravitreal ranibizumab (Drug)
结局指标
主要结局
The effect of intravitreal ranibizumab on serum VEGF level
时间窗: 1 day before and 1 day, 3 days, 1 week after intravitreal ranibizumab
the changes of the serum VEGF levels
次要结局
- The effect of intravitreal ranibizumab on neurologic development(corrected age of six month)
- The effect of intravitreal ranibizumab on height(corrected age of six month)
- The effect of intravitreal ranibizumab on weight(corrected age of six month)